Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CFO Gina Consylman sold 3,594 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $14.66, for a total transaction of $52,688.04. Following the completion of the sale, the chief financial officer now directly owns 59,125 shares in the company, valued at $866,772.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Ironwood Pharmaceuticals, Inc. (NASDAQ IRWD) traded up $0.27 during mid-day trading on Thursday, hitting $14.82. 1,043,563 shares of the stock traded hands, compared to its average volume of 1,930,000. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87. Ironwood Pharmaceuticals, Inc. has a twelve month low of $12.89 and a twelve month high of $19.94. The stock has a market cap of $2,220.00, a price-to-earnings ratio of -18.76 and a beta of 1.28.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. Ironwood Pharmaceuticals had a negative net margin of 39.20% and a negative return on equity of 2,458.64%. The firm had revenue of $94.20 million during the quarter, compared to the consensus estimate of $88.86 million. During the same quarter in the prior year, the firm earned ($0.12) EPS. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. research analysts expect that Ironwood Pharmaceuticals, Inc. will post -0.46 EPS for the current year.
Several research firms have recently issued reports on IRWD. BidaskClub raised shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, February 11th. ValuEngine raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th. Morgan Stanley reissued a “hold” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, December 4th. Zacks Investment Research lowered shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, Bank of America lowered shares of Ironwood Pharmaceuticals from a “buy” rating to an “underperform” rating and lowered their target price for the stock from $20.00 to $15.00 in a research note on Friday, January 5th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $17.56.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.